COVID-19 studies:  C19 studies: C19:  IvermectinIVM Vitamin DV.D HC QHC Q Vitamin CV.C ZincZn PVP-IPVP-I REGNREGN LY-CoVLY RemdesivirRMD
HCQ study #63 of 231
6/18 Late treatment study
Paccoud et al., Clinical Infectious Diseases, doi:10.1093/cid/ciaa791 (Peer Reviewed)
Compassionate use of hydroxychloroquine in clinical practice for patients with mild to severe Covid-19 in a French university hospital
Source   PDF   Share   Tweet
Retrospective of 89 hospitalized patients, survival HR 0.89 [0.23-3.47], not statistically significant. Authors note that unmeasured confounders may have persisted and the study may be underpowered.

Paccoud et al., 6/18/2020, retrospective, France, Europe, peer-reviewed, 20 authors.
risk of death, 11.0% lower, RR 0.89, p = 0.88, treatment 21 of 38 (55.3%), control 26 of 46 (56.5%), adjusted per study.
Details of all 231 studies    Meta analysis
Please send us corrections, updates, or comments.
Submit